We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+19.15%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.86B
AUM Growth
+$577M
Cap. Flow
+$413M
Cap. Flow %
22.17%
Top 10 Hldgs %
49.85%
Holding
103
New
20
Increased
27
Reduced
19
Closed
9

Top Buys

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$21.4M
2
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$20.5M
3
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$16M
4
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$14.4M
5
ADXS
Advaxis Inc
ADXS
+$13.6M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$68.3M
2
TVTX icon
Travere Therapeutics
TVTX
+$21.9M
3
UAM
Universal American Corp
UAM
+$12.1M
4
AMPH icon
Amphastar Pharmaceuticals
AMPH
+$11.1M
5
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 75.61%
2 Technology 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRMD icon
51
iRadimed
IRMD
$1.21B
$8.28M 0.44%
355,684
-1,680
-0.5% -$30.7K
BLRX
52
BioLineRX
BLRX
$12.3M
$8.25M 0.44%
5,167
– –
VCYT icon
53
Veracyte
VCYT
$4.52B
$8.2M 0.44%
+736,196
New +$7.25M
VSTM icon
54
Verastem
VSTM
$532M
$7.92M 0.43%
87,500
– –
FLXN
55
DELISTED
Flexion Therapeutics, Inc.
FLXN
$7.62M 0.41%
348,204
– –
TENX icon
56
Tenax Therapeutics
TENX
$385M
$7.26M 0.39%
62
– –
GNMX
57
DELISTED
Aevi Genomic Medicine Inc
GNMX
$6.83M 0.37%
1,113,900
+88,900
+9% +$689K
TNXP icon
58
Tonix Pharmaceuticals
TNXP
$157M
– –
0
– –
SCYX icon
59
SCYNEXIS
SCYX
$37M
$6.81M 0.37%
+9,688
New +$6.95M
RDHL
60
Redhill Biopharma
RDHL
$3.85M
$6.77M 0.36%
384
-100
-21% -$1.59M
ARAY icon
61
Accuray
ARAY
$28.4M
$6.74M 0.36%
1,000,000
+300,000
+43% +$2.23M
ABMD
62
DELISTED
Abiomed Inc
ABMD
$6.57M 0.35%
+100,000
New +$6.64M
CASC
63
DELISTED
Cascadian Therapeutics, Inc.
CASC
$6.36M 0.34%
283,333
-300,000
-51% -$4.75M
NVDQ
64
DELISTED
Novadaq Technologies Inc.
NVDQ
$6.34M 0.34%
523,863
+200,000
+62% +$2.39M
EGLT
65
DELISTED
Egalet Corporation
EGLT
$6.27M 0.34%
+434,750
New +$4.77M
PLXP
66
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$6.04M 0.32%
59,375
– –
BDSI
67
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$5.97M 0.32%
+750,000
New +$6.44M
CFRX
68
DELISTED
ContraFect Corporation
CFRX
$5.96M 0.32%
+1,773
New +$7.19M
XOMA
69
DELISTED
Xoma
XOMA
$5.82M 0.31%
75,000
– –
ALBO
70
DELISTED
Albireo Pharma Inc
ALBO
$5.75M 0.31%
186,001
+141,667
+320% +$4.76M
VXRT
71
DELISTED
Vaxart
VXRT
$5.41M 0.29%
237,428
– –
WINT
72
DELISTED
Windtree Therapeutics Inc
WINT
$5.32M 0.29%
558,750
-17,857
-3% -$251K
COLL icon
73
Collegium Pharmaceutical
COLL
$1.14B
$5.3M 0.28%
+297,200
New +$5.14M
DRRX
74
DELISTED
DURECT Corp
DRRX
$5.25M 0.28%
219,538
-170,912
-44% -$4.02M
PGNX
75
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$4.48M 0.24%
600,000
-300,000
-33% -$1.81M
1 2
3
4 5

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Broadfin Capital held 103 positions worth $1.86B, up 45% from $1.28B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Broadfin Capital deployed $413M of net new capital in Q2 2015, opening 20 new positions and adding to 27 existing holdings. Its largest new stake was NEVRO CORP.: 419,559 shares worth $22.6M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 92% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $68.3M trimmed.

  • Broadfin Capital's largest Q2 2015 buy was NEVRO CORP.: 419,559 shares worth $22.6M.
  • Broadfin Capital added most to Pernix Therapeutics Holdings, Inc. in Q2 2015, an estimated $20.5M increase.
  • Broadfin Capital's biggest Q2 2015 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $68.3M.
  • Broadfin Capital fully exited Universal American Corp in Q2 2015, selling an estimated $12.1M.
  • Broadfin Capital's ten largest holdings make up 50% of its $1.86B portfolio in Q2 2015.
  • Broadfin Capital opened 20 new positions and closed 9 in Q2 2015.
  • Broadfin Capital's portfolio value rose 45% quarter-over-quarter to $1.86B.

Based on Broadfin Capital's 13F filing for Q2 2015, filed 14 Aug 2015.